Literature DB >> 15472643

Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications?

Guillermo Romero-Farina1, Jaume Candell-Riera, Enrique Galve, Lluís Armadans, Francisca Ramos, Joan Castell, Santiago Aguadé, Juan M Nogales, Jordi Soler-Soler.   

Abstract

BACKGROUND: Some myocardial perfusion single photon emission computed tomography (SPECT) and radionuclide ventriculography studies have suggested that the presence of regional perfusion defects and diastolic abnormalities could have prognostic implications in patients with hypertrophic cardiomyopathy (HC). The aim of this prospective study was to analyze the prognostic value of these techniques in adult patients with HC. METHODS AND
RESULTS: One hundred one patients with HC (44 women; mean age, 54 +/- 16 years; 55% obstructive) were prospectively studied by means of myocardial perfusion SPECT and radionuclide angiography. Of these patients, 55 (54.4%) had an abnormal myocardial perfusion SPECT study: 28 (27.7%) had fixed defects and 41 (40.6%) had reversible defects; 15 (14.8%) of these patients had both types of defect. Of the patients, 16% had left ventricular ejection fraction lower than 60%, 25.7% had an abnormal peak filling rate, and 51% had an abnormal time to peak filling rate. During 5.6 +/- 2.7 years of follow-up, 13 patients (12.8%) died (heart failure 8 and sudden death in 5) and 14 had one or more severe complications develop (syncope in 6, angina III-IV in 4, dyspnea III-IV in 10, and acute myocardial infarction in 3). The summed difference score was higher in patients with cardiac death (2.2 +/- 2.3 vs 1.1 +/- 1.3, P = .008), and fixed defects were more prevalent in patients with severe complications (57% vs 21%, P = .01). In the Kaplan-Meier survival plot analysis, severe complications were more likely in patients with fixed defects (P = .01) or ejection fraction lower than 60% ( P = .01).
CONCLUSIONS: Prognostic information from myocardial perfusion SPECT and radionuclide angiography has limited clinical significance with regard to cardiac death in adult patients with HC. However, the presence of fixed defects and lower ejection fraction in these patients has an adverse prognostic meaning for severe complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472643     DOI: 10.1016/j.nuclcard.2004.05.008

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  37 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome.

Authors:  M Yamada; P M Elliott; J C Kaski; K Prasad; J N Gane; C M Lowe; Y Doi; W J McKenna
Journal:  Eur Heart J       Date:  1998-03       Impact factor: 29.983

Review 3.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

4.  Isovolumic relaxation period in hypertrophic cardiomyopathy: assessment by radionuclide angiography.

Authors:  S Betocchi; R O Bonow; S L Bacharach; D R Rosing; B J Maron; M V Green
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

5.  Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Nuclear Cardiology.

Authors:  B L Zaret; A Battler; H J Berger; M M Bodenheimer; J S Borer; M Brochier; P G Hugenholtz; H N Neufeld; M E Pfisterer
Journal:  Eur Heart J       Date:  1984-10       Impact factor: 29.983

6.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Authors:  B J Maron; I Olivotto; P Spirito; S A Casey; P Bellone; T E Gohman; K J Graham; D A Burton; F Cecchi
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

7.  Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features.

Authors:  W McKenna; J Deanfield; A Faruqui; D England; C Oakley; J Goodwin
Journal:  Am J Cardiol       Date:  1981-03       Impact factor: 2.778

8.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

9.  Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography.

Authors:  P T O'Gara; R O Bonow; B J Maron; B A Damske; A Van Lingen; S L Bacharach; S M Larson; S E Epstein
Journal:  Circulation       Date:  1987-12       Impact factor: 29.690

10.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Iacopo Olivotto; Pietro Bellone; Maria Rosa Conte; Franco Cecchi; Björn P Flygenring; Susan A Casey; Thomas E Gohman; Sergio Bongioanni; Paolo Spirito
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

View more
  5 in total

1.  Prognostic Significance of Myocardial Ischemia Detected by Single-Photon Emission Computed Tomography in Children with Hypertrophic Cardiomyopathy.

Authors:  Lidia Ziolkowska; Agnieszka Boruc; Dorota Sobielarska-Lysiak; Agnieszka Grzyb; Joanna Petryka-Mazurkiewicz; Łukasz Mazurkiewicz; Grazyna Brzezinska-Rajszys
Journal:  Pediatr Cardiol       Date:  2021-03-09       Impact factor: 1.655

2.  Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis.

Authors:  Qun Liu; Diandian Li; Alan E Berger; Roger A Johns; Li Gao
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

3.  In hypertrophic cardiomyopathy reduction of relative resting myocardial blood flow is related to late enhancement, T2-signal and LV wall thickness.

Authors:  Katja Hueper; Antonia Zapf; Jan Skrok; Aurelio Pinheiro; Thomas A Goldstein; Jie Zheng; Stefan L Zimmerman; Ihab R Kamel; Roselle Abraham; Frank Wacker; David A Bluemke; Theodore Abraham; Jens Vogel-Claussen
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

4.  Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement.

Authors:  Adriana D M Villa; Eva Sammut; Niloufar Zarinabad; Gerald Carr-White; Jack Lee; Nuno Bettencourt; Reza Razavi; Eike Nagel; Amedeo Chiribiri
Journal:  J Cardiovasc Magn Reson       Date:  2016-01-14       Impact factor: 5.364

Review 5.  Phenotypes of hypertrophic cardiomyopathy. An illustrative review of MRI findings.

Authors:  Rafaela Soler; Cristina Méndez; Esther Rodríguez; Roberto Barriales; Juan Pablo Ochoa; Lorenzo Monserrat
Journal:  Insights Imaging       Date:  2018-10-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.